UNASSIGNED: The aim of the study was to evaluate VAI and LAP in women with PCOS and to correlate them with metabolic and endocrine markers. The study also assessed these parameters amongst different PCOS phenotypes and determined their usefulness to define metabolically healthy PCOS (MH-PCOS) and metabolically unhealthy PCOS (MU-PCOS).
UNASSIGNED: The design of the study was a cross-sectional study.
UNASSIGNED: Two hundred PCOS women were included in the study, and all the clinical, anthropometric, hormonal, biochemical and metabolic markers were assessed. The cohort was divided into MH-PCOS and MU-PCOS by the modified National Cholesterol Education Programme criteria. VAI and LAP were calculated and correlated with clinical, endocrine and metabolic parameters.
UNASSIGNED: Univariate and multivariate logistic regression analysis was used to study the independent role of VAI and LAP to predict MetS. Adjusted and unadjusted odds ratios were calculated. Receiver-operating characteristic (ROC) analysis was done to define cut-offs in Asian Indian women.
UNASSIGNED: VAI and LAP had good ability to correctly discriminate MU-PCOS from MH-PCOS (area under the curve [AUC] [95% confidence interval (CI)]: 0.89 [0.82-0.95]) and (AUC [95% CI [0.81-0.92] =0.86) using ROC, respectively. The sensitivity of VAI and LAP corresponding to the optimal cut-off of ≥2.76 and ≥48.06 (Youden) was 84.09% and 79.55%, respectively. Similarly, the specificity of VAI and LAP was 85.26% and 79.49%, respectively. VAI has a positive predictive value of 61.7% (95% CI [23.7%-40.3%]) and a negative predictive value of 95% (95% CI [88%-99.1%]). LAP has a positive predictive value of 53% (95% CI [40.3%-65.4%]) and a negative predictive value of 93.3% (95% CI [87.6%-96.9%]). PCOS women having VAI ≥ 2.76 had 19.3 times ([95% CI: 6.50-57.70]) more chance of developing MetS. PCOS women having LAP (≥48.06) have 3.7 times ([95% CI: 1.35-10.60]) more odds. There was no difference between ROC curves of VAI and LAP (P = 0.32).
UNASSIGNED: VAI cut-off ≥ 2.76 and LAP with a cut-off of ≥ 48.06 may be used as markers for predicting MetS amongst PCOS women.
■该研究的目的是评估PCOS女性的VAI和LAP,并将其与代谢和内分泌标志物相关联。该研究还评估了不同PCOS表型中的这些参数,并确定了它们对定义代谢健康PCOS(MH-PCOS)和代谢不健康PCOS(MU-PCOS)的有用性。
■研究的设计是横断面研究。
■两百名PCOS女性被纳入研究,和所有的临床,人体测量学,荷尔蒙,生化和代谢标志物进行评估.根据修改的国家胆固醇教育计划标准,该队列分为MH-PCOS和MU-PCOS。计算VAI和LAP,并与临床相关,内分泌和代谢参数。
■单因素和多因素逻辑回归分析用于研究VAI和LAP在预测MetS中的独立作用。计算调整后和未调整后的赔率比。进行了接收者工作特征(ROC)分析,以定义亚洲印度女性的截止值。
■VAI和LAP具有良好的区分MU-PCOS和MH-PCOS的能力(曲线下面积[AUC][95%置信区间(CI)]:0.89[0.82-0.95])和(AUC[95%CI[0.81-0.92]=0.86)使用ROC,分别。与≥2.76和≥48.06(Youden)的最佳截止值相对应的VAI和LAP的灵敏度分别为84.09%和79.55%,分别。同样,VAI和LAP的特异性分别为85.26%和79.49%,分别。VAI的阳性预测值为61.7%(95%CI[23.7%-40.3%]),阴性预测值为95%(95%CI[88%-99.1%])。LAP的阳性预测值为53%(95%CI[40.3%-65.4%]),阴性预测值为93.3%(95%CI[87.6%-96.9%])。VAI≥2.76的PCOS女性发生MetS的机会增加了19.3倍([95%CI:6.50-57.70])。患有LAP(≥48.06)的PCOS女性的几率更高3.7倍([95%CI:1.35-10.60])。VAI和LAP的ROC曲线差异无统计学意义(P=0.32)。
■VAI截止值≥2.76和LAP截止值≥48.06可用作预测PCOS女性MetS的标志物。